Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

Fig. 2

Proportion of patients with dactylitis stratified by location (patients with baseline DSS > 0). Data for a right hand fingers, b left hand fingers, c right foot toes, and d left foot toes were pooled from OPAL Broaden and OPAL Beyond. *Comparisons where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. Dactylitis was defined as swelling of an entire digit; DSS ranged from 0 to 60 (60 = highest dactylitis severity) [20]. BID twice daily, CI confidence interval, DSS Dactylitis Severity Score, N total number of patients with DSS > 0 at baseline, n number of patients applicable for each category

Back to article page